Matinas BioPharma Holdings, Inc. (MTNB) shareholders
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Robert J. Eide Joint filing with Pembroke & Partners LLC (9.99%) | 16,895,712 | 9.99% | 13D (active) amendment | Apr 8, 2025 |
| Stern Adam K | 2,972,524 | 9.99% | 13D (active) amendment | Jun 10, 2026 |
| Hezbay Holdings LLC | 1,306,488 | 9.54% | 13G (passive) | Jul 13, 2026 |
| Lazar David E. | 545,000 | 9.81% | 13G (passive) | Aug 15, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MTNB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 4,736 | 0.03% | $43.48K | +2,831 | 0.00% |
| BlackRock, Inc. | 3,351 | 0.02% | $30.76K | +41 | 0.00% |
| Geode Capital Management, LLC | 3,276 | 0.02% | $30.08K | −1,068 | 0.00% |
| Vanguard Capital Management LLC | 2,674 | 0.02% | $24.55K | – | 0.00% |
| Holos Integrated Wealth LLC | 2,165 | 0.01% | $20.17K | – | 0.01% |
| Vanguard Fiduciary Trust Co | 1,154 | 0.01% | $10.60K | −64 | 0.00% |
| Susquehanna International Group, Llp | 1,073 | 0.01% | $9.85K | +118 | 0.00% |
| Citadel Advisors LLC | 1,031 | 0.01% | $9.47K | −2,416 | 0.00% |
| State Street Corp | 1,021 | 0.01% | $9.38K | – | 0.00% |
| Sargent Investment Group, LLC | 848 | 0.01% | $7.79K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 190 | 0.00% | $1.75K | – | 0.00% |
| Vanguard Global Advisers, LLC | 89 | 0.00% | $819 | – | 0.00% |
| Morgan Stanley | 23 | 0.00% | $211 | – | 0.00% |
| Costello Asset Management, INC | 13 | 0.00% | $122 | – | 0.00% |
| Wells Fargo & Company/Mn | 7 | 0.00% | $62 | – | 0.00% |
| Jones Financial Companies Lllp | 4 | 0.00% | $39 | – | 0.00% |
| EverSource Wealth Advisors, LLC | 4 | 0.00% | $37 | – | 0.00% |
| Vision Financial Markets LLC | 3 | 0.00% | $26 | – | 0.00% |
| Osaic Holdings, Inc. | 3 | 0.00% | $31 | – | 0.00% |
| Rothschild Investment LLC | 1 | 0.00% | $9 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 25 | 0M | 0.1% | 2 / 3 | 3 / 5 | 0M | 0M |
| Q1 2026 | 28 | 0M | 0.2% | 5 / 2 | 7 / 5 | 0M | 0M |
| Q4 2025 | 30 | 0M | 0.2% | 8 / 4 | 3 / 6 | 0M | 0M |
| Q3 2025 | 28 | 0M | 0.1% | 5 / 7 | 1 / 1 | 0M | 0M |
| Q2 2025 | 24 | 0M | 0.1% | 3 / 3 | 3 / 4 | 0M | 0M |
| Q1 2025 | 25 | 0M | 0.1% | 5 / 5 | 3 / 2 | 0M | 0M |
| Q4 2024 | 22 | 0M | 0.2% | 8 / 1 | 7 / 3 | 0M | 0M |
| Q3 2024 | 17 | 0M | 0.2% | 17 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jerome D. Jabbour | President and CEO, Director | 810,011 | 5.51% | May 2, 2025 |
| An Evelyn D | Director | – | – | Nov 9, 2026 |
| Edward Neugeboren | Director | – | – | Nov 9, 2026 |
| Keith Murphy | Director | – | – | Nov 9, 2026 |
| Robin L. Smith | Director | – | – | May 2, 2025 |
| Partners LLC Sanitam | 10% owner | – | – | Aug 13, 2026 |
| Adam K. Stern | 10% owner | 1,231,445 | 8.38% | Aug 13, 2026 |
| & Partners LLC Pembroke | 10% owner | – | – | Apr 10, 2025 |
| Robert J. Eide | 10% owner | 3,000 | 0.02% | Apr 10, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adam K. Stern 10% owner | Jul 10, 2026 | Option exercise | +344,710 | $0.35 | $120.65K | 416,900 |
| Adam K. Stern 10% owner | Jul 10, 2026 | Option exercise | +630,335 | $0.35 | $220.62K | 743,785 |
| Adam K. Stern 10% owner | Oct 31, 2025 | Option exercise | +92,100 | $0.64 | $58.94K | 113,450 |
| Herbert J. Conrad Director | Jun 22, 2022 | Gift | +1,358,122 | – | – | 4,694,566 |
| Herbert J. Conrad Director | Jun 22, 2022 | Gift | −1,358,122 | – | – | 0 |
| Matthew Wikler Director | Dec 31, 2021 | Award | +7,859 | – | – | 290,472 |
| Matthew Wikler Director | Sep 30, 2021 | Award | +6,106 | – | – | 282,613 |
| Raphael J. Mannino Chief Scientific Officer | Sep 3, 2021 | Other | +462,150 | – | – | 1,919,715 |
| Herbert J. Conrad Director | Aug 4, 2021 | Gift | −494,622 | – | – | 0 |
| Herbert J. Conrad Director | Aug 4, 2021 | Gift | +494,622 | – | – | 3,336,444 |
| Herbert J. Conrad Director | Jul 7, 2021 | Gift | −1,280,917 | – | – | 1,358,122 |
| Herbert J. Conrad Director | Jul 7, 2021 | Gift | +1,280,917 | – | – | 2,841,822 |
| Matthew Wikler Director | Jun 30, 2021 | Award | +10,244 | – | – | 276,507 |
| Jerome D. Jabbour President and CEO, Director | Jun 19, 2021 | Other | +6,000 | – | – | 810,011 |
| Jerome D. Jabbour President and CEO, Director | Jun 19, 2021 | Conversion | +30,000 | – | – | 840,011 |
| Eric J. Ende Director | Jun 19, 2021 | Conversion | +24,000 | – | – | 144,092 |
| Eric J. Ende Director | Jun 19, 2021 | Other | +4,800 | – | – | 120,092 |
| Matthew Wikler Director | Jun 19, 2021 | Other | +2,400 | – | – | 254,263 |
| Matthew Wikler Director | Jun 19, 2021 | Conversion | +12,000 | – | – | 266,263 |
| Raphael J. Mannino Chief Scientific Officer | Jun 19, 2021 | Conversion | +20,000 | – | – | 1,457,565 |
| Raphael J. Mannino Chief Scientific Officer | Jun 19, 2021 | Other | +8,000 | – | – | 1,437,565 |
| James S. Scibetta Director | Jun 19, 2021 | Other | +4,800 | – | – | 625,958 |
| James S. Scibetta Director | Jun 19, 2021 | Conversion | +24,000 | – | – | 649,958 |
| Herbert J. Conrad Director | Jun 19, 2021 | Conversion | +200,000 | – | – | 1,560,905 |
| Herbert J. Conrad Director | Jun 19, 2021 | Other | +40,000 | – | – | 1,360,905 |
| Herbert J. Conrad Director | May 20, 2021 | Gift | +1,145,905 | – | – | 1,320,905 |
| Herbert J. Conrad Director | May 20, 2021 | Gift | −1,145,905 | – | – | 0 |
| Matthew Wikler Director | Mar 31, 2021 | Award | +7,560 | – | – | 251,863 |
| Herbert J. Conrad Director | Jan 13, 2021 | Gift | −50,000 | – | – | 494,622 |
| Herbert J. Conrad Director | Jan 13, 2021 | Gift | +50,000 | – | – | 175,000 |
| Matthew Wikler Director | Dec 31, 2020 | Award | +11,673 | – | – | 244,303 |
| Matthew Wikler Director | Sep 30, 2020 | Award | +20,725 | – | – | 232,630 |
| Adam K. Stern Director | Aug 21, 2020 | Buy | +20,000 | $0.83 | $16.60K | 3,301,983 |
| Matthew Wikler Director | Jun 30, 2020 | Award | +20,537 | – | – | 211,905 |
| Raphael J. Mannino Chief Scientific Officer | Jun 23, 2020 | Other | +3,000 | – | – | 1,429,565 |
| Herbert J. Conrad Director | Jun 23, 2020 | Other | +30,000 | – | – | 544,622 |
| Jerome D. Jabbour President and CEO, Director | Jun 23, 2020 | Other | +4,500 | – | – | 804,011 |
| James S. Scibetta Director | Jun 23, 2020 | Other | +3,600 | – | – | 621,158 |
| Matthew Wikler Director | Jun 23, 2020 | Other | +1,800 | – | – | 191,368 |
| Eric J. Ende Director | Jun 23, 2020 | Other | +3,600 | – | – | 115,292 |
| Adam K. Stern Director | Jun 23, 2020 | Other | +25,500 | – | – | 3,281,983 |
| Herbert J. Conrad Director | Jun 4, 2020 | Gift | −2,639,039 | – | – | 125,000 |
| Herbert J. Conrad Director | Jun 4, 2020 | Gift | +2,639,039 | – | – | 2,639,039 |
| Patrick G. Lepore Director | May 14, 2020 | Buy | +100,000 | $0.73 | $73.00K | 400,000 |
| Herbert J. Conrad Director | May 13, 2020 | Gift | +2,639,039 | – | – | 2,764,039 |
| Herbert J. Conrad Director | May 13, 2020 | Gift | −2,639,039 | – | – | 1,145,905 |
| Adam K. Stern Director | Apr 3, 2020 | Option exercise | +278,407 | $0.50 | $139.20K | 1,337,399 |
| Matthew Wikler Director | Mar 31, 2020 | Award | +26,450 | – | – | 189,568 |
| Adam K. Stern Director | Mar 17, 2020 | Buy | +10,000 | $0.65 | $6.50K | 10,000 |
| Jerome D. Jabbour President and CEO, Director | Mar 17, 2020 | Buy | +10,000 | $0.65 | $6.50K | 799,511 |
| Matthew Wikler Director | Dec 31, 2019 | Award | +6,994 | – | – | 163,118 |
| James S. Scibetta Director | Dec 31, 2019 | Award | +8,260 | – | – | 617,558 |
| Herbert J. Conrad Director | Dec 31, 2019 | Award | +10,573 | – | – | 514,622 |
| Keith A. Kucinski Chief Financial Officer | Nov 25, 2019 | Buy | +58,000 | $1.23 | $71.34K | 94,500 |
| Keith A. Kucinski Chief Financial Officer | Nov 22, 2019 | Buy | +36,500 | $1.20 | $43.80K | 36,500 |
| Patrick G. Lepore Director | Nov 15, 2019 | Buy | +100,000 | $1.06 | $106.00K | 300,000 |
| Herbert J. Conrad Director | Sep 30, 2019 | Award | +38,066 | – | – | 504,049 |
| James S. Scibetta Director | Sep 30, 2019 | Award | +29,739 | – | – | 606,898 |
| Matthew Wikler Director | Sep 30, 2019 | Award | +25,179 | – | – | 154,924 |
| Eric J. Ende Director | Aug 20, 2019 | Buy | +20,000 | $0.66 | $13.20K | 109,292 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Matinas BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 64,559 shares on Sep 15, 2026 over the last 90 days.
See a number that looks wrong?